BCL2L1 and hepatocellular carcinoma: This is in line with previous studies, demonstrating that sorafenib treatment of Bcl-xL-deficient mice showed no increased liver injury and that combined application with BH3-mimetics in leukemia or HCC xenograft mice was well tolerated and resulted in only mild thrombocytopenia [46–48].